Oncolytics Biotech Inc.
- Biotech or pharma, therapeutic R&D
Oncolytics is a clinical-stage biotechnology company developing pelareorep, an intravenously delivered immunotherapeutic agent. Pelareorep has demonstrated promising results in two randomized Phase 2 studies in metastatic breast cancer and Phase 1 and 2 studies in pancreatic cancer. It acts by inducing anti-cancer immune responses and promotes an inflamed tumor phenotype — turning “cold” tumors “hot” — through innate and adaptive immune responses to treat a variety of cancers.
Oncolytics plans to start in 2025 a large Phase 2 study designed to support an accelerated approval in HR+/HER2- metastatic breast cancer, and is working closely with the Global Coalition for Adaptive Research (GCAR) to design an adaptive phase 3 trial in metastatic pancreatic cancer
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}